Acid Blocker Use Has Not Declined Following Celebrex Launch, PBM Finds
Executive Summary
The introduction of Searle/Pfizer's Celebrex has not caused an immediate decrease in use of antisecretory drugs despite the COX-2 inhibitor's selling point of potential gastrointestinal protection compared to traditional non-steroidal anti-inflammatory drugs, an Advance Paradigm managed care study suggests.